Український Журнал Нефрології та Діалізу (Jan 2022)

Association of serum uric acid with albuminuria in type 2 diabetic patients with comorbid obesity and/or essential arterial hypertension

  • M. Marushchak,
  • I. Krynytska,
  • A. Lepyavko

DOI
https://doi.org/10.31450/ukrjnd.1(73).2022.07
Journal volume & issue
no. 1(73)

Abstract

Read online

Abstract. Decompensation of diabetes mellitus type 2 (T2DM), duration of the disease, level of proteinuria, obesity and essential arterial hypertension (AH) play the main role in the development and progress of diabetic nephropathy. The present study aimed to analyze the level of serum uric acid in type 2 diabetic patients with comorbid overweight/obesity and AH and to find its possible correlations with lipid panel data and urinary albumin excretion. Methods. 579 medical records of type 2 diabetic patients treated at the Endocrinological department of the municipal non-profit enterprise "Ternopil University Hospital" of Ternopil Regional Council (Ternopil) in 2018-2019 years were analyzed. Results. The analysis of renal panel data of type 2 diabetic patients with comorbid overweight/obesity and AH found out that only serum levels of urea and uric acid were statistically different in the patients with only T2DM and comorbid course of T2DM. Herewith the maximal changes were established for serum uric acid level, which in type 2 diabetic patients with comorbid obesity exceeded by 175.9 % data of only T2DM patients. Moreover, it was established a significant direct relationship between serum uric acid level and BMI and dyslipidemia in both groups of type 2 diabetic patients - with comorbid obesity and with comorbid obesity and AH. At the same time, a significant direct association between serum uric acid level and albuminuria was established only in type 2 diabetic patients with comorbid obesity and AH. Conclusions. Our retrospective study indicates that serum uric acid level is markedly elevated and positively associated with albuminuria in type 2 diabetic patients with comorbid obesity and AH and can be used as a biomarker allowing further risk stratification for development and/or progress of diabetic nephropathy in this cohort of the patients.

Keywords